1型糖尿病中人类胰腺间充质基质细胞的表征
研究用多重免疫组化在人胰腺切片中鉴定胰腺间充质基质细胞(pMSCs),样本来自38名供者,共分析53,375个pMSCs和26,376个胰岛。结果显示pMSCs组成性表达ANXA1,1型糖尿病患者含胰岛素胰岛周围pMSCs密度增高,而胰岛素缺乏胰岛周围密度降低,且晚发患者胰岛周围pMSCs密度更高。
要点
- pMSCs位于胰岛外周,33.2%组成性表达ANXA1,提示其具有胰岛保护作用。
- 1型糖尿病患者含胰岛素胰岛的pMSCs密度较无糖尿病者增高(p<0.001)。
- ≥13岁诊断者的胰岛外周pMSCs密度高于<13岁诊断者(p<0.001)。
核心结论
- pMSCs组成性表达ANXA1,提示其在健康状态下具有胰岛保护作用。
- 1型糖尿病中含胰岛素胰岛周围pMSCs密度增高,胰岛素缺乏胰岛周围密度降低,与胰岛保护假说一致。
- 晚发1型糖尿病者胰岛外周pMSCs密度更高,与较弱免疫细胞浸润相关。
研究设计与样本
- 采用多重免疫组化在人胰腺切片中鉴定pMSCs(CD90+/CD105+/CD73+/CD31-/CD45-/CD34-)。
- 样本来自38名供者(Network for Pancreatic Organ Donors with Diabetes和Exeter Archival Diabetes Biobank)。
- 供者分为<13岁诊断1型糖尿病(n=8)、≥13岁诊断(n=11)及年龄相近的无糖尿病性别匹配个体。
- 共鉴定53,375个pMSCs,分析26,376个胰岛。
- 培养扩增的MSCs暴露于细胞因子后用流式细胞术评估活力和增殖。
主要发现
- pMSCs在人胰腺中呈纺锤样形态包绕胰岛外周。
- 33.2%的pMSCs表达ANXA1,且在有无糖尿病个体中均组成性表达。
- 1型糖尿病患者含胰岛素胰岛的胰岛内及胰岛外周10 µm内pMSCs密度均高于无糖尿病者(p<0.001)。
- ≥13岁诊断者胰岛外周10 µm内pMSCs密度高于<13岁诊断者(p<0.001)。
- 糖尿病患者胰岛素缺乏胰岛周围pMSCs密度低于含胰岛素胰岛(p<0.001)。
关键数值与推荐
- pMSCs表型定义为CD90+/CD105+/CD73+/CD31-/CD45-/CD34-。
- 胰岛外周pMSCs定义为距胰岛边缘10 µm以内。
- ANXA1在33.2%的pMSCs中表达。
临床怎么用
- pMSCs可作为1型糖尿病胰岛保护与免疫调节的潜在研究方向。
- 胰岛外周pMSCs密度可能反映胰岛存活状态及免疫浸润强度。
- 早发1型糖尿病者pMSCs在较强促炎环境中存活能力下降,可能与β细胞快速丢失相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Culture-expanded mesenchymal stromal cells (MSCs) reduce immune cell activation and improve islet functional survival. However, little is known about human pancreatic MSCs (pMSCs) in health or how they are altered in type 1 diabetes. Here, we determined the number, density and islet-protective phenotype of pMSCs in situ in individuals with and without type 1 diabetes. METHODS: Multiplex immunohistochemistry was used to identify pMSCs (CD90+/CD105+/CD73+/CD31-/CD45-/CD34-) in human pancreas sections from 38 donors (Network for Pancreatic Organ Donors with Diabetes and Exeter Archival Diabetes Biobank). Donors were categorised as either <13 years at type 1 diabetes diagnosis (n=8) or ≥13 years at type 1 diabetes diagnosis (n=11) or were sex-matched individuals of similar age without diabetes. Consecutive sections were immunostained with antisera against insulin, glucagon and the established islet-protective and immunomodulatory factors annexin A1 (ANXA1) and indoleamine 2,3-dioxygenase 1. Whole-slide scans were acquired and pMSCs either inside or at the periphery (within 10 µm) of islets were quantified on an individual-islet basis. We identified 53,375 pMSCs and performed an analysis of 26,376 individual islets. Culture-expanded MSCs were exposed to cytokines and viability and proliferation were assessed by flow cytometry. RESULTS: pMSCs were identified in situ in the human pancreas where they wrap around the islet periphery in an expected spindle-like morphology. ANXA1 was expressed by 33.2% of pMSCs and was expressed constitutively among individuals with or without diabetes. The density of both intraislet pMSCs and pMSCs within 10 µm of the islet periphery was increased for insulin-containing islets in individuals with type 1 diabetes compared with individuals without diabetes (p<0.001). pMSC density within 10 µm of the islet periphery was preferentially increased in individuals ≥13 years at type 1 diabetes diagnosis compared with individuals <13 years at type 1 diabetes diagnosis (p<0.001). pMSC density was reduced around insulin-deficient islets compared with insulin-containing islets in individuals with diabetes (p<0.001), consistent with an islet-protective role for pMSCs. Exposure of culture-expanded MSCs to an aggressive cytokine combination led to increased cell death and reduced proliferation. CONCLUSIONS/INTERPRETATION: pMSCs express ANXA1 constitutively, suggesting an islet-protective role in health. The density of pMSCs was increased around insulin-containing islets and lost around insulin-deficient islets in individuals with type 1 diabetes which aligns with this hypothesis. pMSC density at the periphery of insulin-containing islets was preferentially higher in individuals with later-onset type 1 diabetes, correlating with a less intense immune cell infiltration. The reduced ability of pMSCs to survive in the more intense proinflammatory environment around islets in younger-onset type 1 diabetes may contribute to the rapid rate of beta cell loss in these individuals.
引用
- Dewhurst-Trigg RE, Atkins J, Morgan NG, et al. Characterisation of human pancreatic mesenchymal stromal cells in type 1 diabetes. Diabetologia. 2025. PMID: 41422462. doi:10.1007/s00125-025-06634-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。